Group 1: Event Details - TianKang Biological Co., Ltd. will participate in the "2023 Xinjiang Listed Companies Investor Collective Reception Day" [1] - The event will be held online on June 16, 2023, from 15:30 to 18:00 [1] - Investors can join via the "Panorama Roadshow" website, WeChat official account, or Panorama Roadshow APP [1] Group 2: Communication Focus - Company executives will discuss the 2022 annual performance, corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [1] - The aim is to enhance interaction and communication with investors [1] Group 3: Assurance of Information - The company and its board guarantee the accuracy and completeness of the disclosed information, ensuring no false records or misleading statements [1]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3,890,843,979.48, representing a 14.71% increase compared to CNY 3,391,929,405.09 in the same period last year[18]. - The net loss attributable to shareholders of the listed company was CNY -14,282,251.76, a significant improvement of 79.48% from CNY -69,605,796.25 year-on-year[18]. - The net profit for the current period was -17,149,045.31, compared to -108,566,710.19 in the previous period, indicating an improvement[32]. - The total comprehensive income for the current period was -7,300,826.24, compared to -188,142,159.14 in the previous period, showing a significant reduction in losses[33]. - The basic and diluted earnings per share for the current period were both -0.01, compared to -0.05 in the previous period[33]. Cash Flow - The net cash flow from operating activities improved by 35.21%, amounting to CNY -523,750,573.77, compared to CNY -808,347,021.44 in the previous year[21]. - Cash flow from operating activities resulted in a net outflow of -523,750,573.77, an improvement from -808,347,021.44 in the previous period[33]. - Cash flow from investing activities generated a net inflow of 474,080,713.81, compared to a net outflow of -204,891,989.28 in the previous period[34]. - Cash flow from financing activities resulted in a net inflow of 651,284,449.71, compared to a net outflow of -122,578,555.00 in the previous period[34]. - The company reported cash and cash equivalents at the end of the period amounting to 3,802,570,554.95, up from 2,175,960,504.84 in the previous period[34]. Assets and Liabilities - The total assets as of March 31, 2023, were CNY 20,374,771,227.30, reflecting a 5.24% increase from CNY 19,360,994,902.71 at the end of the previous year[18]. - The total liabilities as of Q1 2023 amounted to approximately RMB 10.61 billion, compared to RMB 9.70 billion in the previous year, indicating a year-over-year increase of 9.4%[30]. - Current assets rose to CNY 12,990,493,336.65, up from CNY 12,412,059,821.41, indicating an increase of about 4.65%[41]. - The total current liabilities increased to CNY 7,315,031,840.16 from CNY 6,173,714,914.84, representing a rise of about 18.46%[42]. - Non-current liabilities decreased to CNY 3,290,328,060.73 from CNY 3,522,309,214.78, showing a reduction of about 6.58%[42]. Equity and Investments - The company’s total equity attributable to shareholders was CNY 8,039,387,885.55, a slight increase of 1.13% from CNY 7,949,867,246.11 at the end of the previous year[18]. - The total equity attributable to minority shareholders was approximately RMB 1.73 billion, compared to RMB 1.72 billion in the previous year, indicating stability in minority interests[30]. - The company's long-term equity investments decreased to CNY 21,357,276.88 from CNY 105,445,142.28, a decline of approximately 79.73%[42]. Research and Development - The company increased its research and development expenditure to CNY 12,982,627.27, a rise of 68.48% from CNY 7,705,622.64 in the previous year[7]. - Research and development expenses for Q1 2023 were approximately RMB 40.16 million, slightly up from RMB 38.13 million in Q1 2022, indicating a focus on innovation[30]. Management and Operational Efficiency - The company reported a decrease in management expenses by 28.63%, amounting to CNY 104,830,863.20 compared to CNY 146,883,773.68 in the previous year[7]. - The company reported a decrease in management expenses to approximately RMB 104.83 million from RMB 146.88 million, showing improved cost management[30]. - The company recorded operating profit of 10,831,007.05, a significant recovery from -87,755,749.48 in the previous period[32]. Strategic Acquisitions - The company completed the acquisition of 100% equity in Guanjie Company, which is now a wholly-owned subsidiary, enhancing its market position[26]. - The company plans to acquire a 100% stake in Guanjie Biotechnology Co., Ltd. for a total price of 655,100,000.00, enhancing its market position[39]. - The company has engaged with 17 counterparties to sign conditional equity transfer agreements, indicating ongoing strategic expansion efforts[26]. Revenue and Costs - Total operating revenue for Q1 2023 was approximately RMB 3.89 billion, an increase of 14.7% compared to RMB 3.39 billion in Q1 2022[30]. - Total operating costs for Q1 2023 were approximately RMB 3.87 billion, up from RMB 3.50 billion in Q1 2022, reflecting a year-over-year increase of 10.6%[30]. - The company reported a total revenue from sales of goods and services amounting to 3,574,616,196.13, compared to 3,148,399,562.50 in the previous period, reflecting growth[33].

Financial Performance - The company reported a non-operating loss of approximately ¥12.39 million in 2022, compared to a loss of ¥30.67 million in 2021, indicating a significant improvement [2]. - Government subsidies recognized in the current period amounted to ¥64.24 million, up from ¥35.44 million in 2021, reflecting a 81.3% increase [2]. - The company achieved a gain of ¥54.50 thousand from investments in subsidiaries, which is a notable recovery from a loss of ¥611.76 thousand in 2020 [2]. - The fair value changes from trading financial assets resulted in a profit of ¥3.75 million, down from ¥6.41 million in 2021, showing a decrease of 41.5% [2]. - In 2022, the company achieved operating revenue of 16.732 billion RMB, an increase of 6.5% compared to the previous year, and net profit attributable to shareholders of 302 million RMB, marking a turnaround from losses [163]. Employee and Governance - The total number of employees at the end of the reporting period was 5,067, with 56 in the parent company and 5,011 in major subsidiaries [26]. - The company has implemented an "excess profit sharing system" as part of its compensation policy to align with its strategic goals [28]. - There are no stock incentive plans for directors and senior management during the reporting period [32]. - The company has 147 employees participating in the employee stock ownership plan, holding a total of 6,363,400 shares, which is 0.47% of the total share capital [33]. - The company’s board of directors actively participated in meetings, with all members attending 12 meetings during the reporting period [50]. Internal Control and Compliance - The internal audit department has strengthened its oversight of the internal control system, enhancing compliance and risk management practices [39]. - The company has established a comprehensive internal control system in accordance with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [39]. - The company reported zero significant deficiencies in financial reporting controls during the reporting period [41]. - There were no material weaknesses identified in internal controls, indicating a strong control environment [42]. - The company has established a robust internal control system to ensure the accuracy and completeness of financial information [91]. Environmental Responsibility - The company has complied with environmental regulations and standards, ensuring responsible operational practices [72]. - The company established an emergency response center led by the general manager to handle environmental pollution incidents, ensuring clear responsibilities and training for staff [75]. - The company has implemented automatic online monitoring equipment for wastewater treatment, measuring parameters such as chemical oxygen demand and ammonia nitrogen [79]. - The company reported a total discharge of 0.00735 tons of chemical oxygen demand and 0.000334 tons of ammonia nitrogen, with no exceedance of discharge standards [99]. - The company has a valid pollution discharge permit until October 28, 2026, for its plant protein production operations [98]. Strategic Development and Market Position - The company plans to enhance its market expansion strategies and product offerings in the upcoming fiscal year [1]. - The company is actively involved in market expansion and product development, particularly in the field of plant-based proteins [90]. - The company aims to become a leading health farming service provider and safe food supplier in China, achieving a complete closed loop in modern animal husbandry across four key areas: breeding, feed management, animal medicine, and meat processing sales [128]. - The company has completed a mixed-ownership reform in its animal health business, introducing new strategic investors and implementing employee stock ownership to enhance business focus and vitality [167]. - The company is enhancing its digital transformation efforts, focusing on cost reduction in breeding, disease prevention, and smart farming [168]. Financial Management and Future Plans - The company plans to distribute cash dividends of 2.2 RMB per 10 shares, totaling approximately 298,010,804.3 RMB (including tax) for the fiscal year 2022 [31]. - The company has committed to a cash dividend distribution of no less than 10% of the distributable profit achieved in the year, with plans for annual distributions over the next three years [118]. - The company plans to increase cash dividend ratios if net profits continue to grow steadily over the next three years [118]. - The company has committed to terminating non-core financial business operations within six months to maintain focus on its primary business [116]. - The company has made adjustments to its accounting practices regarding research and development expenditures and sales rebates, impacting its profit and tax liabilities [123][139]. Industry Insights - In 2022, China's pig inventory reached 452.56 million heads, an increase of 3.34 million heads or 0.74% year-on-year, while the slaughter volume was 699.95 million heads, up 28.67 million heads or 4.27% year-on-year [143]. - The animal vaccine industry is supported by national policies aimed at improving animal disease prevention systems, with a focus on innovation and large-scale production [146]. - The implementation of the new veterinary drug GMP standards is expected to lead to industry consolidation, improving product quality and increasing market concentration [147]. - The veterinary drug industry experienced a significant reduction in profitability in the first half of 2022, but began to recover in the second quarter, with a positive trend in revenue and profit in the third quarter [148]. - The total output of the national feed industry reached 30.223 million tons in 2022, a growth of 3.0% year-on-year, with a significant increase in bulk feed sales by 18.5% [157].

天康生物 为充分尊重投资者、提升交流的针对性，现就公司 2022 年年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投资者可通过访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。问题征集截至 2023 年 5 月 15 日（星期一）17:00。 公司将在 2022 年年度业绩说明会上，在信息披露允许的范围内对投资 者普遍关注的问题进行回答。 天康生物 | 证券代码：002100 | 证券简称：天康生物 | 公告编号：2023-049 | | --- | --- | --- | | 债券代码：128030 | 债券简称：天康转债 | | 天康生物股份有限公司 关于举行 2022 年年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 天康生物股份有限公司（以下简称"公司"）将于 2023 年 5 月 16 日（星期二）下午 15：00—17：00 举行 2022 年年度报告网上业绩 说明会，本次年度报告说明会将采用网络远程方式召开，投资者可登 陆 "全景·路演天下"（http:/ ...

Group 1: Business Operations - The company employs a "sales-driven production and sales" strategy to effectively control operational risks while leveraging the plant protein business to support the feed business [2] - The feed business in Xinjiang maintains good growth, while the Central Plains region experiences slow growth, and the Northeast region faces significant challenges [3] Group 2: Vaccine Business - The animal vaccine business saw substantial growth in 2014, primarily due to a surge in sales of small ruminant disease vaccines and stable growth in government tendered vaccines [3] - The company is actively seeking breakthroughs in market-oriented marketing for its vaccine products [3] Group 3: Asset Restructuring - The company has submitted feedback to the China Securities Regulatory Commission (CSRC) regarding its major asset restructuring, which is currently under review by the CSRC [3]

证券代码：002100 证券简称：天康生物 新疆天康畜牧生物技术股份有限公司 投资者关系活动记录表 编号：2015-003 | --- | --- | --- | |-----------------------|-------------------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 申万宏源孙利群、牟冰旋、李一民、董樑、龚毓幸；华宝信托杨 | | 人员姓名 | | 丽、中天证券张帆、南方资产胡纪元、中融人寿毛新旺、国金通 | | | 产刘之意 | 用基金欧阳正杰、兴业基金吴刚、华宝兴业基金傅盈、泰康资 | | | | | | 时间 | 2015 年 8 月 4 日 | | | 地点 | ...

证券代码：002100 证券简称：天康生物 新疆天康畜牧生物技术股份有限公司 投资者关系活动记录表 编号：2015-006 | --- | --- | --- | |-----------------------|-------------------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华夏基金李彦； | 安信证券刘哲铭。 | | 人员姓名 | | | | 时间 | 2015 年 11 月 9 日 | | | 地点 | 新疆乌鲁木齐市高新区长春南路 4 号会议室 | 528 号天康企业大厦 11 楼 | | 上市公司接待人 员姓名 | 董事会秘书郭运江 | | | 投资者关系活动 | 1 | 、询问公司疫苗 ...

Group 1: Company Overview - Xinjiang Tiankang Animal Husbandry Biotechnology Co., Ltd. is involved in a major asset restructuring, currently in the process of merging with Tiankang Holding Group [1]. - The company has received approval from the China Securities Regulatory Commission for the asset transfer related to the merger [1]. Group 2: Impact of Market Conditions - Recent fluctuations in pig prices have positively influenced the company's performance in the first half of the year, with national pig prices currently on the rise [2]. - The company anticipates that its pig farming capacity could reach 500,000 heads following the merger [2]. Group 3: Business Development - Post-merger, the company will establish a full industry chain structure encompassing animal vaccines, feed, plant protein, breeding, pig farming, slaughter processing, and meat product sales [2]. - The animal vaccine business experienced significant growth in 2014, with stable government procurement and ongoing efforts to enhance market-driven sales [2].

Group 1: Company Structure and Operations - The company has completed the acquisition of its controlling shareholder, forming a full industry chain structure including biological vaccines for livestock, feed and plant protein, breeding of breeding pigs, pig farming, slaughter processing, and meat product sales in Xinjiang [2]. Group 2: Business Performance and Growth - The government tender for vaccines is maintaining stable growth, while market-oriented marketing is striving for breakthroughs [3]. - The plant protein business is operating normally, effectively controlling operational risks, and is expected to maintain profitability [3]. - Future profit growth is anticipated to focus on the biopharmaceutical and breeding sectors [3]. Group 3: International Collaboration - Currently, there are no overseas cooperation intentions, but there may be future contacts in this area [3].

证券代码：002100 证券简称：天康生物 新疆天康畜牧生物技术股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |-------------------------|-----------------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 国泰君安王乾、财通基金王宇颖、光大保德信基金龙飞 | | 时间 | 2015 年 6 月 16 日 | | | | | | | 地点 | 新疆乌鲁木齐市高新区长春南路 董秘办公室 | 528 号天康企业大厦 11 楼 | | 上市公司接待人 员姓名 | 董事会秘书郭运江 | | | 投资者关系活动 | 1、询问公司 ...